drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (anti-CD20)
drug_description
Type I anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity and ADCC.
nci_thesaurus_concept_id
C1702
nci_thesaurus_preferred_term
Rituximab
nci_thesaurus_definition
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
drug_mesh_term
Rituximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Type I anti‑CD20 chimeric monoclonal antibody that binds CD20 on B cells and depletes them primarily via complement‑dependent cytotoxicity (CDC) and antibody‑dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP), leading to elimination of CD20‑positive B cells.
drug_name
Rituximab
nct_id_drug_ref
NCT06084936